Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026)
Alkermes' (ALKS) quarterly Depreciation & Amortization (CF) came in at $19.4 million in Q1 2026, up 161.81% year-on-year from $7.4 million in Q1 2025, and up 405.17% on a QoQ basis from $3.8 million in Q4 2025.
Alkermes (ALKS) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $19.4 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 161.81% year-over-year to $19.4 million in Q1 2026; TTM through Mar 2026 was $39.2 million, a 40.42% increase from a year earlier, with the FY2025 full-year figure at $27.2 million, down 4.79% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $19.4 million, up from $3.8 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ALKS reached as high as $19.7 million in Q4 2022 and fell as low as $3.8 million in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $13.4 million across 5 years, with a median of $18.5 million in 2023.
- Across the five-year window, Depreciation & Amortization (CF) plunged 64.98% in 2024 and jumped 161.81% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $19.7 million in 2022, then fell by 5.77% to $18.5 million in 2023, then slumped by 63.07% to $6.8 million in 2024, then tumbled by 43.83% to $3.8 million in 2025, then soared by 405.17% to $19.4 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $19.4 million in Q1 2026, $3.8 million in Q4 2025, and $8.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 19.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.43 Mn |
| Mar 31, 2026 | 19.43 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Jun 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Sep 30, 2024 | 6.97 Mn |
| Sep 30, 2024 | 6.97 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 6.66 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Mar 31, 2024 | 8.06 Mn |
| Dec 31, 2023 | 18.54 Mn |
| Dec 31, 2023 | 18.54 Mn |